



HAL
open science

Coupled impedance & field potential data analysis of in vitro cardiomyocyte assays

Levy Batista, Leo Doerr, Matthias Beckler, Niels Fertig, Thierry Bastogne

► To cite this version:

Levy Batista, Leo Doerr, Matthias Beckler, Niels Fertig, Thierry Bastogne. Coupled impedance & field potential data analysis of in vitro cardiomyocyte assays. Safety Pharmacology Society 2017 Annual Meeting, SPS 2017, Sep 2017, Berlin, Germany. hal-01669436

HAL Id: hal-01669436

<https://hal.science/hal-01669436v1>

Submitted on 20 Dec 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Coupled Impedance & Field Potential Data Analysis of in vitro Cardiomyocyte Assays

L. BATISTA^{1,2,3}, L. DOERR⁴, M. BECKLER⁴, N. FERTIG⁴, T. BASTOGNE^{1,2,3}
¹CRAN, ²INRIA BIGS, ³CYBERnano, ⁴NANION

Background. One goal of the Comprehensive in vitro ProArrhythmia Assay initiative is to predict more accurately potentially torsadogenic compounds in an earlier stage of drug development. To that aim one of the CiPA component is to assess capabilities of label-free in vitro assays (impedance and extracellular field potential signals) applied to human stem cell-derived cardiomyocytes.

Objectives

Impedance and extracellular field potential signals belong to the class of **high-content data** for which the most challenging issue to be addressed is to identify **predictive biomarkers of cardiotoxicity** in a large amount of data. To that aim, **new statistical signal-processing methods** are needed and the objective of this study is to develop a non-supervised technique able to rank the contractility and electrophysiological effects of tested compounds.

Methods

The CardioExcyte 96 (Nanon Technologies GmbH) is used to measure both **impedance** and **extracellular field potential** signals on two **CiPA** compounds applied to cardiomyocytes. The developed method for data processing firstly computes nine numerical indicators. They characterize the time variations of frequency, amplitude, shape and irregularity of cell impedance and field potential signals. The ninth parameter is the cardiomyocyte viability index. In a second phase, statistical tests are applied on each characteristics to evaluate the concentration effect of the tested compounds. Finally, results of the previous statistical results are aggregated in a **cardio-effect score**, graduated from 0 (no influence) to 18 (highly disturbed beating). This innovative approach was tested using in vitro data obtained from two molecules (1 cardiotoxic and 1 non-cardiotoxic compounds).

Results

Results have emphasized some **correlations** but also some **differences** between the cardio-effects detected between the two types of signals. For the first tested compound, the absence of effects is detected by the two measurements. For the second compound, effects are detected but the modified characteristics are different in impedance and field potential signals.

Conclusion

The proposed computation method automates the combined analysis of impedance and extracellular field potential measurements on cardiomyocytes. Complementary effects have been **detected** by the data analysis for the impedance and field potential signals. This comparative study will be soon extended to a larger batch of molecules for **validation**




Fig.1: Two types of signals
 Top : Impedance (IMP). Bottom: Extracellular field potential (EFP)




Fig.2: Characterization of each sweep with 5 indicators (IMP) among the time (4 indicators for EFP)




Fig.3: Scores calculated on all indicators. Left: No statistically significant effect. Right: A dose-response information appears but on different indicators between IMP and EFP




Fig.4: Estimation of the EC50 profiles. Left: Flat model meaning no effect. Right: EC50 values estimation based on the Hill's model